Stay updated with breaking news from Simbec Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.
Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) rose 6% following the successful completion of the phase I study for its lead...
Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) (OCT) hailed as a "major milestone" the successful completion of dosing for all cohorts...
Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) has successfully administered the final dose of its lead drug candidate, OCT461201, as...
/PRNewswire/ -- DelveInsight's Menopause Market Insights report includes a comprehensive understanding of current treatment practices, menopause emerging...